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Discontinuation of in vitro fertilisation (IVF) cycles has been part of the radical 
transformation of healthcare provision to enable reallocation of staff and resources to deal 
with the COVID-19 pandemic. We sought to estimate the impact of cessation of treatment on 
individual prognosis and United States population live-birth rates. 
Design 
Data from 271,438 ovarian stimulation UK IVF cycles was used to model the effect of age as 
a continuous, yet non-linear, function on cumulative live-birth rate. We recalibrated this 
model to cumulative live-birth rates reported for the 135,6733 stimulation cycles undertaken 
in the USA in 2016, with live-birth follow-up to October 2018.  We calculated the effect of a 
one-month, three-month and six-month shutdown in IVF treatment as the effect of the 
equivalent increase in a woman’s age, stratified by age group.  
Results 
The average reduction in cumulative live-birth rate would be 0.3% [95% CI: 0.3, 0.3], 0.8% 
[0.8, 0.8] and 1.6% [1.6, 1.6] for a one-month, three-month and six-month shutdown, 
respectively. This corresponds to a reduction of 369 [95% CI; 360, 378), 1,098 [1071, 1123] 
and 2,166 [2,116, 2,216] live-births in the cohort, respectively. The greatest contribution to 
this reduction was from older mothers.  
Conclusions 
We demonstrate that the discontinuation of fertility treatment for even 1 month in the USA 
could result in 369 fewer women having a live-birth, due to the increase in patients’ age 
during the shutdown. As a result of reductions in cumulative live-birth rate, more cycles may 




Discontinuation of the 2.5 million in vitro fertilisation (IVF) cycles performed annually 
(Fauser, 2019), has been part of the radical transformation of healthcare provision to enable 
reallocation of staff and resources to deal with the COVID-19 pandemic. As of 14 March 
2020 the European Society for Human Reproduction and Embryology (ESHRE), the 
American Society for Reproductive Medicine (ASRM), and other international professional 
bodies all recommended that assisted reproduction treatments should no longer be 
commenced, with national authorities aligning to ensure rapid cessation of treatment and 
prevention of overburdening healthcare systems. The success rates of infertility treatment are 
however acutely time sensitive, with progressive monotonic declines with advancing 
maternal age from age 34 years (Smith, et al., 2015). With most cycles starting in women 
older than 34 (e.g. in the US ~61% >35years and mean age at ovarian stimulation 35.5 in the 
UK and 38.0 in Japan (Ishihara, et al., 2020), it is likely that a temporary shutdown of IVF 
treatment could cause a reduction in the number of IVF live-births. Even as clinical services 
are recommenced, they are likely to be at differential rates depending on local resources and 
policies, with the potential for variable delays in treatment. The purpose of this short 
communication is to estimate the extent of such a reduction in individual prognosis and 
population live-birth rates. 
 
Methods 
We used data from the Human Fertilisation and Embryology Authority (HFEA) on IVF 
treatment in the UK to model the effect of age on cumulative live-birth rate. The HFEA 
dataset recorded age in years, without groups, which allowed us to model the effect of age as 
a continuous, yet non-linear, function (Smith, et al., 2019, Smith, et al., 2015). This model 
was then recalibrated to the most recent cumulative live-birth rates reported for the USA by 
 
 
the Centers for Disease Control and Prevention (CDC) as detailed in the latest Assisted 
Reproductive Technology Fertility Clinic Success Rates Report (CDC, 2019).  The 
development model incorporated 158,197 women undergoing 271,438 ovarian stimulation 
cycles for IVF in the UK between January 1, 2003 and December 31, 2010, with follow-up of 
all embryo transfers until June 30, 2012. The recalibration model incorporated the 135,673 
stimulation cycles undertaken by the 448 clinics in the USA that were commenced between 
January 1, 2016 and December 31, 2016, with inclusion of all embryo transfers that occurred 
within 12 months, and live-birth follow-up to October 2018 (CDC, 2019). The cumulative 
live-birth rate was defined as the probability of a live-birth from an ovarian stimulation 
encompassing all subsequent fresh and frozen embryo transfers from that stimulation. In the 
US this was time limited to an embryo transfer occurring within 12 months. In the UK live-
birth was defined as birth of one or more infants born alive after 24 weeks gestation surviving 
more than one month, while in the US live-birth was defined as birth one or more infants with 
any sign of life (CDC, 2019). Full details of the model and assumptions are given in 
supplementary material. We calculated the effect of a one-month, three-month and six-month 
shutdown in IVF treatment as the effect of the equivalent increase in a woman’s age, 
stratified by age group.  
 
Results 
Our model showed the decline in cumulative live-birth rate is observable from 33 years of 
age, for women using their own oocytes (Supplemental Figure 1). Table 1 shows the 
estimated effect of shutdowns of various duration on the cumulative live-birth rate, and the 
estimated reduction in number of IVF live births in the US CDC cohort, stratified by age. The 
average reduction in cumulative live-birth rate would be 0.3% [95% CI: 0.3, 0.3], 0.8% [0.8, 
0.8] and 1.6% [1.6, 1.6] for a one-month, three-month and six-month shutdown, respectively. 
 
 
This corresponds to a reduction of 369 [95% CI; 360, 378], 1,098 [1071, 1123] and 2,166 
[2,116, 2,216] live-births in the cohort, respectively. Older mothers would contribute 
disproportionately to this reduction, with a one month delay resulting in 2.9% [95% CI; 2.8, 
2.9] fewer live-births from 41-42 year olds as compared to 0.35% [95% CI; 0.3, 0.4] fewer 
births from women ≤35 years old.  
 
Discussion 
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and the coronavirus disease 
2019 (COVID-19) pandemic has been responsible for the transformation of infertility service 
provision. We demonstrate that the discontinuation of fertility treatment for even 1 month in 
the USA could result in 369 fewer women having a live-birth, due to the increase in patients’ 
age during the shutdown. There was evidence of divergence on the overall contribution to 
live-births with increasing maternal age, with older women greatest affected by delays in 
treatment.  
 
Due to the pre-existing legal regulations and new HFEA guidance introduced in 2015, the 
equivalent UK data for cumulative live-births could not be obtained. We sought to recalibrate 
our model for the most recent population dataset reporting cumulative live birth outcomes 
with an extended follow-up to allow for frozen embryos to be included in the analysis (CDC, 
2019). By using cumulative live-birth from a single ovarian stimulation cycle, thereby 
allowing for the transfer of fresh or frozen embryos, and by accounting for multiple births as 
a single event, differences in clinical practice between the UK and US will have been 





Recommencement of infertility services needs to occur soon, as accommodating social 
distancing working patterns and other SARS-CoV-2 transmission risk mitigation measures 
are likely to impact further on capacity facilitating further delays. Whether the rapid rises in 
US unemployment and / or fear of engaging with the healthcare sector or concerns regarding 
pregnancy and perinatal outcomes despite reassuring data (ACOG 2020), will further 
contribute to a reduction in clinical activity on reopening is unclear. Accurate quantification 
of the overall impact will not be available for several years due to the timelines of CDC, and 
equivalent data custodians in other countries (e.g. HFEA in the UK) reporting or making data 
available on cumulative live-births, and we acknowledge that this may be less or greater than 
modelled here. Further national or local SARS-CoV-2 epidemics, or even another pandemic, 
are possible, and that would mean our results were an underestimate and the long-term 
consequences considerable. The personal and societal toll of the cessation of infertility 
treatments, despite being recommended for only a short period of time by both ASRM and 
ESHRE, is likely to have an unrecognised persistent emotional and economic impact for 
many patients and staff. Particularly as the re-initiation and regaining of patient confidence in 
healthcare services may take substantially longer than the simple reversal of a professional 
bodies edict. Irrespective of the drivers, more cycles may be required to overcome infertility 
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Estimated changes in cumulative live-birth rates and number of live-births associated with shutdown 
of IVF treatment, by age of patient, in sample of 135,673 IVF cycles representing one year of 
treatment provision. 
Age group (years) < 35 35-37 38-40 41-42 >42 
Number of cycles per year* 52,428 28,996 28,287 14,358 11,604 
Without shutdown      
Estimated cumulative  
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Our analyses our based on our paper on “Live-birth rate associated with repeat in vitro 
fertilisation treatment cycles”;1 details on ethical approval, source of data, eligibility criteria 
and definitions are given in the published paper. For the purposes of developing the model we 
also included cycles from women who had already had an IVF live-birth and excluded oocyte 
retrievals occurring before a live-birth from an embryo replacement from an earlier retrieval. 
This resulted in a cohort of 158,197 women undergoing 271,438 ovarian stimulation cycles 
for IVF in the UK between January 1, 2003 and December 31, 2010, with follow-up until 
June 30, 2012. 
 
Couple and treatment characteristics 
The covariates included in the model were selected on the basis of previous publications 
showing that they were related to within-cycle live-birth rate,2,3 and that they would be 
available before a treatment cycle, i.e. available at the time when most treatment decisions 
are typically made. These were: woman’s age (in years), number of previous cycles of IVF, 
duration of infertility (in years attempting to have a live birth), previous IVF pregnancy or 
live birth, and cause of infertility (tubal, ovulatory, endometriosis, or male cause). The 
treatment characteristics were oocyte source (autologous or donor), sperm source (woman’s 
partner or donor), and whether ICSI was performed.  
 
Statistical model selection 
Our estimates of the effect of age on within-cycle live-birth rate are derived from a prediction 
model for the number of cycles of IVF required before a live birth. This model was 




repeat in vitro fertilisation treatment cycles”,1 but detail of this model did not appear in the 
published version. 
 
We fitted logistic regression models for the effect of couple and treatment characteristics on 
within-cycle live-birth rate in UK (HFEA) data. We included a different intercept for each 
number of previous IVF cycles. This adjusts the model for the number of previous IVF 
cycles. It further has the advantage that it allowed us to model the number of IVF cycles 
required before a live birth, although this was only relevant to the published paper and not the 
current analysis.  
 
We initially examined the univariable association of each covariate with within-cycle live-
birth rate. Age and duration of infertility were considered as ordinal variables in the existing 
literature,2-6 but both variables were measured continuously (in whole numbers of years) in 
the UK (HFEA) database. A nonlinear relationship between age, duration of infertility and 
live-birth rate has previously been shown.3,6 Hence the shapes of the associations between 
delivery rate and age and duration of infertility were modelled with linear splines. A stepwise 
procedure was used to select knots from a list that included a knot at every different year. As 
there was of a differing association between age and live-birth rate for autologous and donor 
oocytes,3,4 we included an interaction between age and oocyte source and allowed the 
stepwise procedure to choose potentially different knots for autologous and donor oocytes. 
Duration of infertility was missing in 3% of cycles. We overcame this by including an 
indicator for missingness as well as the spline model for the association between duration of 





After selecting the shape of the associations of age and duration of infertility, we examined 
multivariable associations of all covariates with within-cycle live-birth rate. We then ran a 
backward stepwise procedure to remove non-significant associations with age, duration of 
infertility, and patient history. We explored the possibility of interactions between age and 
oocyte source, age and duration of infertility, sperm source and oocyte source, and sperm 
source, male cause and ICSI by including interactions terms in the regression. These 
interactions were explored because of their biological plausibility and evidence from previous 
publications of their existence in relation to live-birth rate.3 All possible interactions between 
the age and duration of infertility splines included in the multivariable model were considered 
by a stepwise procedure. Finally, we ran a backward stepwise procedure to remove spurious 
interactions from the model. We included 3-way interactions whenever the final model 
selection contained all 3 relevant 2-way interactions. The stepwise regression procedures 
were based on the likelihood ratio test, and used p-value thresholds that were calculated, 
according to Bonferroni correction and the closed testing procedure,7 to give a family-wise 
type I error of 5%. 
 
Model details 
We developed our model using the UK (HFEA) data for 271,438 ovarian stimulation cycles 
undertaken between January 1, 2003 and December 31, 2010 with follow-up to June 30, 
2012. For autologous oocytes, the stepwise procedure selected a linear spline with knots 
(changes in gradient) at 26, 33, 36 and 40 years. For donor oocytes, there was no association 
between woman’s age and delivery rate. For duration of infertility, the stepwise procedure 
selected a linear spline with a knot at 4 years. The interactions selected were between oocyte 




infertility and ICSI. Multivariable associations in the model with interaction terms are shown 
in Table S1. 
 
Since these data are from UK cycles initiated between 2003 and 2010 our model required 
recalibration for the US analysis of the effect of stopping IVF treatment. This is because 
overall IVF live-birth rates are likely to differ between the UK and US, and live-birth rates in 
both countries have increased since the data in our models were collected. Recalibration was 
based on the Centers for Disease Control and Prevention. 2017 Assisted Reproductive 
Technology Fertility Clinic Success Rates Report using 2017 as the most recent year for 
which complete data is available8.  Age is grouped in the CDC data, so we identified a 
nominal age within each group to use for recalibration of the model. These nominal ages are 
shown in Table S2. We recalibrated the model by adding a constant to the model intercept, 
calculated such that the overall within-cycle live-birth rate (for all ages) predicted by the 
recalibrated model would be equal to the overall observed within-cycle live-birth rate. Table 
S2 shows that the recalibrated model underestimated the within-cycle live-birth rate for 
women aged less than 35 years and overestimated for all other age groups. However, a 
calibration regression showed no evidence of unacceptable calibration of the model 
(regression slope 1.125, [95% CI 0.782 to 1.467]). We estimated that the effect of 
miscalibration of this magnitude could change our estimated reduced number of live births by 
at most 31, 91 and 180 live births respectively for a one-month, three-month and six-month 
shutdown respectively, a maximum relative difference of 8%. 
 
Assumptions of our analyses 
The recalibration of our model makes several assumptions. We have used nominal ages (in 




groups (in the CDC data). This assumes an even distribution of ages within the age groups. 
This seems a reasonable approximation when age groups span only 2-3 years. We varied the 
nominal ages for the larger age groups, but the calibration did not appear to be sensitive to 
this choice (data not shown). We assumed that the decline in within-cycle live-birth rate with 
age is similar in both populations. When recalibrating our model, we did not detect any 
difference between the US in 2017 and the UK in 2003 to 2010 with follow-up to June 30, 
2012. However, further validation of the model is required before it could be used to inform 
clinical practice or individual prognosis in either population. The original model is adjusted 
for other patient and treatment characteristics measured in the UK between 2003 and 2010. 
These are likely to differ in the US in 2017. However, our estimated reduction in within-cycle 
live-birth rates was calculated based on age alone, not these other patient and treatment 
characteristics. Although it is possible that the effect of age may depend on these other 
patient and treatment characteristics, this was not found in the development of our model as 
the odds ratios highlighted in Table S1 differed by less than 1% from those found in 
univariate analysis (data not shown).  
 
Our estimation of the reduction in within-cycle live-birth rate associated with shutdown of 
IVF treatment also makes certain assumptions. In assessing one-month, three-month and six-
month shutdowns, we have assumed that the shutdown lasts the same length of time across all 
clinics. It is likely that restrictions due to COVID-19 will start and stop at different times in 
different locations. Our calculations do not take into account the possibility of patients 
moving their treatment to clinics (potentially in other countries) not affected by the shutdown, 
but this seems unlikely due to travel restrictions. We have also assumed that the shutdown 
applies to all patients regardless of their age; if treatment is restricted to some age groups but 




assumed that the number and age-distribution of IVF cycles is comparable in 2020 and 2017. 
It is likely that the number of IVF patients has increased between 2017 and 2020 (at least 
prior to the outbreak of COVID-19) so we have potentially underestimated the reduction in 
number of live births due to shutdown.  
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Associations between couple and treatment characteristics and per-cycle delivery rate from a model 
based on 271,438 IVF cycles undertaken by 158,197 women. Model adjusted for cycle number. 
  Odds ratio (95% CI)    
Age and oocyte source  
Autologous oocytes, age 18  
Autologous oocytes, slope 18-26  
Autologous oocytes, slope 26-33  
Autologous oocytes, slope 33-36  
Autologous oocytes, slope 36-40  
Autologous oocytes, slope 40-53  
Donor oocytes, age 21-55  
  
1  
1.081 (1.057, 1.104)  
0.990 (0.984, 0.996)  
0.925 (0.916, 0.935)  
0.825 (0.817, 0.833)  
0.664 (0.648, 0.680)  
1.865 (1.576, 2.206)  
  
Duration of infertility (with observed data)  
Missing   
Slope up to 4 years  
4 years  
Slope after 4 years   
  
1  
0.945 (0.936, 0.953)  
0.963 (0.916, 1.012)  
0.977 (0.974, 0.981)  
  
IVF history  
No previous IVF pregnancy  
Previous IVF pregnancy  
  
1  
1.584 (1.533, 1.636)  
  




No cause above identified   
  
0.910 (0.889, 0.932)  
1.032 (1.006, 1.060)  
0.953 (0.919, 0.988)   
1  
  
  No male cause of 
infertility identified  
Male cause of infertility  
Partner sperm, IVF only  
Partner sperm, IVF and ICSI  
Donor sperm, IVF only  
Donor sperm, IVF and ICSI  
1  
1.103 (1.074, 1.133)  
1.265 (1.145, 1.397)  
1.390 (1.247, 1.548)  
0.647 (0.623, 0.673)  
1.137 (1.113, 1.161)  
1.583 (1.466, 1.710)  
1.610 (1.447, 1.791)  
Donor oocytes and sperm  0.620 (0.508, 0.757)    






Comparison of within-cycle live-birth rates in observed data (135,673 IVF cycles undertaken in the 
US in 2017) and estimated by a recalibrated model (originally based on 271,438 IVF cycles 
undertaken in the UK between 2003 and 2010). 
 
Observed data       
Age group (years) < 35 35-37 38-40 41-42 >42 All ages 
Within-cycle live-birth rate 51.6% 37.5% 23.5% 11.8% 3.4% 34.4% 












Estimation based on 
recalibrated model 
      
Nominal age (years) 33 36 39 41.5 44  
Within-cycle live-birth rate 46.3% 40.6% 27.7% 14.6% 5.8% 34.4% 

















Supplemental Figure 1 
Association between age, oocyte source, and cumulative live-birth rate, from a model based on 
271,438 IVF cycles undertaken by 158,197 women in the UK between 2003 and 2010 with follow-up 
to June 2012. Baseline levels are recalibrated based on 135,673 IVF cycles undertaken in the US in 
2017. 
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